These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 26044568)
1. The Epidemiological, Mechanistic and Potential Clinical Role of Androgen Receptor (AR) in Urothelial Carcinoma. Bourlon MT; Flaig TW Curr Drug Targets; 2016; 17(2):196-205. PubMed ID: 26044568 [TBL] [Abstract][Full Text] [Related]
2. Androgen receptor promotes the migration and invasion of upper urinary tract urothelial carcinoma cells through the upregulation of MMP-9 and COX-2. Chen CC; Hsieh TF; Chang CH; Ma WL; Hung XF; Tsai YR; Lin MH; Zhang C; Chang C; Shyr CR Oncol Rep; 2013 Aug; 30(2):979-85. PubMed ID: 23715826 [TBL] [Abstract][Full Text] [Related]
3. Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder. Boorjian SA; Heemers HV; Frank I; Farmer SA; Schmidt LJ; Sebo TJ; Tindall DJ Endocr Relat Cancer; 2009 Mar; 16(1):123-37. PubMed ID: 18845648 [TBL] [Abstract][Full Text] [Related]
4. Epigenetic regulation of Elf5 is associated with epithelial-mesenchymal transition in urothelial cancer. Wu B; Cao X; Liang X; Zhang X; Zhang W; Sun G; Wang D PLoS One; 2015; 10(1):e0117510. PubMed ID: 25629735 [TBL] [Abstract][Full Text] [Related]
5. Role of the androgen receptor in urothelial cancer. Inoue S; Mizushima T; Miyamoto H Mol Cell Endocrinol; 2018 Apr; 465():73-81. PubMed ID: 28652170 [TBL] [Abstract][Full Text] [Related]
6. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer. Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513 [TBL] [Abstract][Full Text] [Related]
7. Context dependent regulatory patterns of the androgen receptor and androgen receptor target genes. Olsen JR; Azeem W; Hellem MR; Marvyin K; Hua Y; Qu Y; Li L; Lin B; Ke X; Øyan AM; Kalland K BMC Cancer; 2016 Jul; 16():377. PubMed ID: 27378372 [TBL] [Abstract][Full Text] [Related]
8. Diagnostic utility of androgen receptor expression in discriminating poorly differentiated urothelial and prostate carcinoma. Downes MR; Torlakovic EE; Aldaoud N; Zlotta AR; Evans AJ; van der Kwast TH J Clin Pathol; 2013 Sep; 66(9):779-86. PubMed ID: 23775437 [TBL] [Abstract][Full Text] [Related]
9. Association of Androgen Receptor Expression on Tumor Cells and PD-L1 Expression in Muscle-Invasive and Metastatic Urothelial Carcinoma: Insights for Clinical Research. Necchi A; Lo Vullo S; Giannatempo P; Raggi D; Perrone F; Nicolai N; Catanzaro M; Biasoni D; Torelli T; Piva L; Stagni S; Salvioni R; Mariani L; Colecchia M Clin Genitourin Cancer; 2018 Apr; 16(2):e403-e410. PubMed ID: 29111177 [TBL] [Abstract][Full Text] [Related]
10. Androgen receptor inducing bladder cancer progression by promoting an epithelial-mesenchymal transition. Jitao W; Jinchen H; Qingzuo L; Li C; Lei S; Jianming W; Zhenli G Andrologia; 2014 Dec; 46(10):1128-33. PubMed ID: 24329492 [TBL] [Abstract][Full Text] [Related]
11. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model. Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672 [TBL] [Abstract][Full Text] [Related]
12. The ErbB family and androgen receptor signaling are targets of Celecoxib in prostate cancer. Brizzolara A; Benelli R; Venè R; Barboro P; Poggi A; Tosetti F; Ferrari N Cancer Lett; 2017 Aug; 400():9-17. PubMed ID: 28450158 [TBL] [Abstract][Full Text] [Related]
13. Effect of type I growth factor receptor tyrosine kinase inhibitors on phosphorylation and transactivation activity of the androgen receptor in prostate cancer cells: Ligand-independent activation of the N-terminal domain of the androgen receptor. Sugita S; Kawashima H; Tanaka T; Kurisu T; Sugimura K; Nakatani T Oncol Rep; 2004 Jun; 11(6):1273-9. PubMed ID: 15138566 [TBL] [Abstract][Full Text] [Related]
14. Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Mahajan NP; Liu Y; Majumder S; Warren MR; Parker CE; Mohler JL; Earp HS; Whang YE Proc Natl Acad Sci U S A; 2007 May; 104(20):8438-43. PubMed ID: 17494760 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo. Wang M; Liu X; Guo J; Weng X; Jiang G; Wang Z; He L Biochem Biophys Res Commun; 2015 Nov; 467(2):310-5. PubMed ID: 26435505 [TBL] [Abstract][Full Text] [Related]
16. Comparison of tyrosine kinase receptors HER2, EGFR, and VEGFR expression in micropapillary urothelial carcinoma with invasive urothelial carcinoma. Li J; Jackson CL; Yang D; Noble L; Wheeler M; MacKenzie D; Adegun T; Amin A Target Oncol; 2015 Sep; 10(3):355-63. PubMed ID: 25293577 [TBL] [Abstract][Full Text] [Related]
17. Transcribed ultraconserved region Uc.63+ promotes resistance to cisplatin through regulation of androgen receptor signaling in bladder cancer. Sekino Y; Sakamoto N; Ishikawa A; Honma R; Shigematsu Y; Hayashi T; Sentani K; Oue N; Teishima J; Matsubara A; Yasui W Oncol Rep; 2019 May; 41(5):3111-3118. PubMed ID: 30864720 [TBL] [Abstract][Full Text] [Related]